Zn-MOF: an efficient drug delivery platform for the encapsulation and releasing of Imatinib Mesylate

Mesoporous Zn-2(BDC)(2)(DABCO)-MOF (BDC = 1,4-benzenedicarboxilic acid, and DABCO = diazabicyclooctane) was synthesized via ball-milling and employed as a good and efficient platform for targeted drug delivery. Imatinib mesylate (IM) was encapsulated in Zn-MOF and IM@Zn-MOF characterized using different technique including X-ray powder diffraction, field emission scanning electron microscopy, transmission electron microscopy, thermogravimetric analysis, inductively coupled plasma, Brunauer-Emmett-Teller surface area analysis. The result showed that small molecules of the IM successfully were encapsulated inside of the Zn-MOF. Releasing of drug-loaded Zn-MOF was studied by UV-vis spectroscopy at 240 nm at in vitro condition in HCl (0.1N) and PBS buffer. Rapid release of IM occurs upon hydrolytic decomposition of MOF in dissolution media.

Automated summary

Mesoporous Zn-2(BDC)(2)(DABCO)-MOF synthesized via ball-milling effectively encapsulated small molecules of Imatinib mesylate, showing rapid drug release upon hydrolytic decomposition in dissolution media under in vitro conditions.